Arkady Nekrasov

Founder of NPO Petrovax Pharm, Professor, Doctor of Chemistry, Winner of the State Prize of the Russian Federation.

  • Company foundation.
  • Registration of the Polyoxidonium® medicine and the Grippol® vaccine.
  • The State Prize of the Russian Federation awarded to the team of creators and developers led by Proffessor A.V. Nekrasov for the creation of innovative medicines Polyoxidonium® and Grippol® and for their implementation in healthcare practice.
  • Opening of the production facilities for manufacture of APIs, soft and solid dosage forms, and injectable forms.
  • The beginning of the partnership with Solvay Pharma (currently, Abbott).
  • Assignment of the International Non-proprietary Name - Azoximer bromide for Polyoxidonium® by WHO.
Полиоксидоний - таблетки 12 мг - Вправо.jpgIn 2002, a team of developers led by Professor A.V. Nekrasov was awarded the State Prize of the Russian Federation for the development and implementation of Polyoxidonium® and Grippol® into healthcare practice.
  • Market launch of Longidaza®.
  • Opening of a modern technological manufacturing and warehouse complex complying with GMP standards in Pokrov Village (Podolsk District, Moscow Region).
  • Launch of a unique line for manufacturing medicinal products in pre-filled syringes.
  • Market launch of innovative preservative-free influenza vaccine Grippol® Plus.
  • Development and production of vaccines against pandemic strain of influenza A/H1N1: MonoGrippol Neo, MonoGrippol Plus, and MonoGrippol.
  • Production of Grippol® Plus vaccine for the National Immunization Schedule.
  • Launch of a localization project of the 13-valent conjugate pneumococcal vaccine manufacturing (in cooperation with Pfizer). The project won in the All-Russian Platinum Ounce Competition.
  • The company successfully passed the EU GMP inspection.
  • Acquisition of a controlling share in NPO Petrovax Pharm by Vladimir Potanin, owner and founder of the Interros Group.
  • Signing agreements on the Grippol® Plus influenza vaccine localization in the Republic of Belarus and Iran.
  • Market launch of the innovative Imoferaza®cosmetic cream (specialized care for scars after injury, surgery, acne).
  • Assignment of the International Non-proprietary Name - bovhyaluronidase azoximer for Longidaza® by WHO.
  • Obtaining official permission from the Ministry of Health of the Russian Federation for manufacture of Russian influenza vaccine – Grippol® Plus – using antigens of the influenza virus produced in Russia by Saint Petersburg Scientific Research Institute of Vaccines and Serums of the FMBA of Russia.
  • The beginnig of cooperation with Boehringer Ingelheim to localize full-cycle production of innovative thrombolytic medicines “Metalyse” and “Actilyse”. Launch of the first commercial batches of Metalyse®.
  • Extending the age of use of Polyoxidonium® in tablets to include children from 3 years old. Successful completion of the Post-Authorization Safety Study (PASS) of Polyoxidonium® in Europe (Slovakia).
  • NPO Petrovax Pharm LLC is the winner of the All-Russian competition sponsored by the Russian Union of Industrialists and Entrepreneurs "Russian Business Leaders: Dynamics and Responsibility – 2017" in the nomination "For Dynamic Business Development".
  • Completion of the clinical trials of Grippol® Quadrivalent, the first Russia’s quadrivalent inactivated subunit adjuvanted influenza vaccine. Autorization dossier submission.

Grippol Welson

  • Market launch of Grippol® Quadrivalent, Russia's first quadrivalent inactivated subunit adjuvanted influenza vaccine. The Petrovax product portfolio was expanded with a new product - Velson® (international nonproprietary name: Melatonin), which helps to speed up falling asleep and improves sleep quality.
  • Launch of a new 3rd line for manufacture of APIs, tablets, and suppositories. Obtaining a license and the Russian GMP certificate for a new manufacturing line. Confirming the production facilities and the Quality Management System (QMS) conformity to EU GMP rules (Slovakia). The first batches of Polyoxidonium® were supplied to Slovakia in accordance with the mandatory requirements for the labeling of medicines in the European Union.
  • Victory of the Company's medicines in the 7th National Pharmaceutical Prize – Russian Pharma Awards: Polyoxidonium® in the nomination "The Medicine of Choice for Treatment and Prevention of Acute Respiratory Viral Infections and Influenza in Children"; Longidaza® in the nomination "The Medicine of Choice for Pathogenetic Therapy of Chronic Prostatitis and Relapse Prevention".
  • Rebranding. The new brand identity represents the Company’s new strategy for expanding the product portfolio and intensive international integration.
1.png Petrovax

  • Large-scale clinical trials program for original medicinal products - Polyoxidonium® and Longidaza® - for prevention and treatment of COVID-19.
  • Putting into operation the 2nd production facility for manufacturing APIs, soft and solid dosage forms. The line allowed to increase the manufacturing of APIs by 2.5 times, suppositories by 4 times and tablets by 7 times.
  • Beggining of the Russian-Chinese project for the development and further production of Convidecia, a recombinant adenovirus-based viral vector vaccine for prevention of COVID-19 in cooperation with CanSino Biologics Inc. (China).
  • Launch of new products:
  • Uronext®, a complex remedy for urinary tract infections.
  • VitaFerr®, a complex product for prevention of iron deficiency among women.
  • New dosage form - Polyoxidonium® solution.
  • Charity support of the Podolsk City Hospital in equipping a COVID hospital. More than 20 thousand packages of Polyoxidonium® are donated to healthcare professionals working in the “red zones” for prevention of COVID-19.

© Petrovax
The materials posted on the site are for informational purposes only and are not intended to advertise or promote the manufacturer or medications produced.